Effects of Metformin on Hormonal Profile and Seminal Fluid Analysis in Obese Infertile Male

Ahmed R. Abu Raghif MBChB PhD
Dept. of Pharmacology, College of Medicine, Al Nahrain University, Baghdad, Iraq

Abstract

Background Overweight and obese men have an up to 50% higher rate of sub-fertility when compared with normal weight men. Possible management options include weight reduction by dieting or surgery and medical treatment to correct specific endocrine abnormalities, but as yet none has been proven to be effective.

Objective To verify the impact of decreasing body mass index by giving metformin on hormonal profile and seminal fluid analysis in obese infertile male.

Methods Eighteen obese patients whose body mass index was 30-40 kg/m² and with mean age of 29 years (range: 22-42 years) with idiopathic asthenozoospermia were enrolled in the study. Standard semen analysis according to WHO and hormones assay which include: follicular stimulating hormone, luteinizing hormone, prolactin, testosterone, and estradiole were performed at baseline and after 12 weeks of therapy. The enrolled patients were asked to take metformin 850 mg twice daily orally for 12 weeks.

Results A significant decrease (p<0.001) in sperm count and sperm activity after 12 weeks of treatment with metformin. While there is no significant differences with respect to other spermiological parameters.

Conclusions Although metformin has the capacity to decrease the level of prolactin, it decreases the number and activity of sperms. Further studies are recommended to investigate whether there is any association between infertility in human males and chronic metformin use

Keywords Metformin, infertility, male, prolactin, overweight, obese.

Introduction

Metformin is one of antidiabetic drugs which belong to the biguanide class of oral antihyperglycemic agents. It was first synthesized in 1929 and was shown to be a potent hypoglycemic agent (1).

Metformin acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance. The effects of metformin include increased glucose uptake, oxidation and muscle glycogenesis, increased glucose metabolism to lactate by the intestine, reduced hepatic gluconeogenesis and possibly a reduced rate of intestinal glucose absorption (2).

The molecular mechanisms of metformin action are not fully known. Activation of the enzyme AMP-activated protein kinase (AMK) appears to be the mechanism by which metformin lowers serum lipid and blood glucose concentrations (3). Metformin works through the Peutz-Jeghers protein, LKB1, to
regulate AMPK. LKB1 is a tumor suppressor and activation of AMPK through LKB1 may play a role in inhibiting cell growth (4).

The incidence of obesity is rapidly rising in almost every region of the world. Although obesity affects women more than men, male obesity is an issue of serious concern. In Europe, the International Obesity Task Force (2005) has indicated that obesity rates in adult men range from 10 to 27%, with this prevalence rising significantly in the last 10 years (5).

The adverse influence of obesity on various aspects of female reproduction and fertility has been realized for sometime (6) and management guidelines are now available (7). More recently, data regarding male obesity and infertility have been accumulating (8,9). There are now several population-based studies showing that overweight and obese men have an up to 50% higher rate of sub-fertility when compared with normal weight men (10,11). One could argue that this could be related to confounding factors such as male age, smoking and alcohol use, and female partner obesity. However, once these factors have been excluded it was shown that for every three-point increase in a man’s BMI, couples were 10% more likely to be infertile (12).

Kort et al. (2007) showed significant negative relationship between high body mass index (BMI) and sperm motility in 528 Danish men. In addition, men with BMI > 25 had fewer chromatin-intact normal-motile sperm cells per ejaculate (13). Jensen et al. (2004) in accordance with other studies showed that overweight and obese men (BMI > 25 kg/m2) had significantly lower sperm concentrations than those of normal-weight men (BMI 20–25 kg/m2) (14). The prevalence of oligozoospermia was higher in overweight and obese men compared with normal-weight men. A substantial decrease in serum testosterone, sex hormone binding globulin and Inhibin B were also found with increasing BMI (14). There are several etiological theories including endocrine abnormalities, genetic, sexual dysfunction and testicular hyperthermia. Of these, endocrine abnormalities are likely to be the most important, involving increased estrogen and increased insulin resistance, reduced androgens and reduced inhibin B levels. Possible management options include weight reduction by dieting or surgery and medical treatment to correct specific endocrine abnormalities, but as yet none has been proven to be effective (15). The aim of current study was to assess the impact of decreasing BMI by giving metformin on hormonal profile and seminal fluid analysis in obese infertile male.

Methods
Patient Selection
Eighteen obese patients (BMI = 30-40 kg/m2) (mean age, 29 years; range, 22–42 years) with idiopathic asthenozoospermia were enrolled in the study. The patients were selected at the Department of Pharmacology, Faculty of Medicine, Al-Nahrain University and Urology Clinic of Al-Imamain Al-Kadhimiyian Medical City, Baghdad, Iraq, at period extended from Apr. 2012 to Sep. 2012. All subjects underwent medical screening, including history and clinical examination, and presented with a clinical history of primary infertility of at least 3 years.

Eligibility Criteria

Safety Assessment
Safety assessment included medical history, physical examination, hematological screening, and serum chemistry at all visits and the monitoring of drug-related adverse events by recordation in patient diaries

Laboratory investigations
Hormones assay include: follicular stimulating hormone (FSH), luteinizing hormone (LH),
prolactin, testosterone, and estradiole (E2) (by miniVIDAS 12 model)

Standard semen analysis: Freshly ejaculated semen samples were obtained by masturbation into sterile petri-dish containers under clean condition after (3-5) days of sexual abstinence. The specimens were placed in an incubator at 37°C for (30) minutes to allow liquefaction, after liquefaction, semen samples were evaluated for semen volume, appearance, pH and viscosity, then specimens were analyzed for sperm concentration, progressive motility and normal morphology according to WHO criteria (16).

Study Design and Treatments
The enrolled patients were asked to take metformin (Merck, France), 850 mg twice daily orally for 12 weeks. Clinical examination, semen analysis, and hormonal assay were performed at baseline and after 12 weeks of therapy. All patients provided their written informed consent and completed the entire trial.

Statistical analysis
The data were analyzed using SPSS program. Results were reported as mean ± S.D. The total variations were analyzed by performing the statistical design T-test. Probability levels of less than 0.05 were considered significant (17).

Results
Metformin treatment was well-tolerated by all subjects. None of the subjects suspended the therapy due to side effects, although some experienced transient diarrhea and flatulence during the first month of treatment.

Effect on BMI
For the mean duration of the study (12 weeks), Metformin was given to 18 patients. The mean BMI decreased significantly during the treatment time, from 35.93 ± 5.7 to 34.85 ± 5.2 (p <0.001).

Effect on seminal fluid analysis
The results of current study shows no significant differences with respect to semen volume, liquefaction time, pH, and normal morphology at baseline and after 3 months of treatment with metformin 850 mg two times / day. The (mean±SD) was (3.04 ± 1.12 vs. 3.08 ± 0.93) (39.17 ± 23.82 vs. 28.75 ± 2.26) (8.21 ± 0.50 vs. 8.21 ± 0.33) (62.08 ± 10.97 vs. 64.58 ± 4.98) before and after 3 months of treatment with metformin for semen volume, liquefaction time, pH, and normal morphology respectively. In this study, the (mean±SD) before versus after 3 months of treatment with metformin 850 mg two times / day for sperm count and sperm activity was (19.00 ± 14.53 vs. 16.13 ± 13.76) (8.33 ± 5.77 vs. 3.83 ± 1.95) respectively. The results shows significant difference (p <0.05) with respect to sperm count and sperm activity at the base line (before treatment) and after 3 months of treatment with metformin (Table 1 and Fig. 1).

Effect on hormonal analysis
The (mean±SD) before versus after 3 months of treatment with metformin of serum LH, FSH, E2, and testosterone was as follows respectively: (4.04 ± 4.21 vs. 3.63 ± 2.76) (7.19 ± 8.84 vs. 6.55 ± 7.77) (5.30 ± 5.54 vs. 4.21 ± 2.69) (4.33 ± 1.51 vs. 3.94 ± 1.18) and it shows no statistically significant differences between baseline and after 3 months of treatment with metformin.

The results of current study reveal statistically significant decrease in the level of serum prolactin before and after 3 months of treatment with metformin with mean±SD of 8.01 ± 5.73 vs. 6.93 ± 5.09.

Discussion:
Obesity has been shown to adversely affect male fertility, by reducing spermatogenesis. There are several etiological theories including endocrine abnormalities, genetic, sexual dysfunction and testicular hyperthermia. Of these, endocrine abnormalities are likely to be the most important, involving increased estrogen and increased insulin resistance, reduced androgens and reduced inhibin B levels (15).
Abu Raghif MR, *Metformin & Obese Infertile Male*

<table>
<thead>
<tr>
<th>Semen parameters</th>
<th>Metformin Treatment</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before (mean± SD)</td>
<td>After (mean± SD)</td>
</tr>
<tr>
<td>Semen volume (ml)</td>
<td>3.04 ± 1.12</td>
<td>3.08 ± 0.93</td>
</tr>
<tr>
<td>liquefaction time (min)</td>
<td>39.17 ± 23.82</td>
<td>28.75 ± 2.26</td>
</tr>
<tr>
<td>pH</td>
<td>8.21 ± 0.50</td>
<td>8.21 ± 0.33</td>
</tr>
<tr>
<td>Sperm count (10^6/ml)</td>
<td>19.00 ± 14.53</td>
<td>16.13 ± 13.76</td>
</tr>
<tr>
<td>Sperm activity %</td>
<td>8.33 ± 5.77</td>
<td>3.83 ± 1.95</td>
</tr>
<tr>
<td>Normal morphology (%)</td>
<td>62.08 ± 10.97</td>
<td>64.58 ± 4.98</td>
</tr>
</tbody>
</table>

Fig. 1. Semen analysis parameters before and after 3 months of treatment with metformin

Insulin resistance could be the underlying pathogenesis of chronic hypospermatogenesis leading to oligospermia and azoospermia associated with other metabolic abnormalities in men. Metformin has proven as an effective medication for not only IR but several other aspects of the polycystic ovarian disease including reproductive abnormalities (15). Therefore, insulin sensitizers, particularly metformin could probably have beneficial effects on overweight and obese patients with asthenozoospermia.
In our study, metformin was effective in reducing BMI significantly. These results are in accordance with recent observations made by several authors, such as Hosokawa et al (18) Garber et al (19) and De Fronzo et al (20) among others. The MOCA trial is the largest double-blind, randomized, placebo-controlled trial of metformin in obese non diabetic children and young people. The MOCA trial provides evidence that a short treatment course of metformin is clinically useful, safe, and well tolerated to halt further gain in adiposity and improve fasting glucose (21).

Table 2. Hormonal analysis before and after 3 months of metformin treatment

<table>
<thead>
<tr>
<th>Hormones</th>
<th>Metformin treatment</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before (mean± SD)</td>
<td></td>
</tr>
<tr>
<td>Luteinizing hormone</td>
<td>4.04 ± 4.21</td>
<td>0.403</td>
</tr>
<tr>
<td>Follicular stimulating hormone</td>
<td>7.19 ± 8.84</td>
<td>0.074</td>
</tr>
<tr>
<td>Prolactin</td>
<td>8.01 ± 5.73</td>
<td>0.019</td>
</tr>
<tr>
<td>Estradiol</td>
<td>5.30 ± 5.54</td>
<td>0.235</td>
</tr>
<tr>
<td>Testosterone</td>
<td>4.33 ± 1.51</td>
<td>0.196</td>
</tr>
<tr>
<td></td>
<td>After (mean± SD)</td>
<td></td>
</tr>
<tr>
<td>Luteinizing hormone</td>
<td>3.63 ± 2.76</td>
<td></td>
</tr>
<tr>
<td>Follicular stimulating hormone</td>
<td>6.55 ± 7.77</td>
<td></td>
</tr>
<tr>
<td>Prolactin</td>
<td>6.93 ± 5.09</td>
<td></td>
</tr>
<tr>
<td>Estradiol</td>
<td>4.21 ± 2.69</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>3.94 ± 1.18</td>
<td></td>
</tr>
</tbody>
</table>

In the current study metformin was given to 18 overweight and obese patients with asthenozoospermia in a dose of 850 mg twice a day for 12 weeks. The results of present study demonstrate that administration of metformin decreases significantly sperm count and sperm activity while there is no statistically significant changes regarding semen volume, liquefaction time, pH, and normal morphology respectively. A study by Naglaa et al showed that oral administration of metformin to both diabetic and non-diabetic rabbits resulted in a significant decrease in testicular weight, sperm count, sperm motility and serum testosterone with a significant increase in sperm anomalies and dead sperm percentage (22). Naglaa et al has suggested that vitamin B12 deficiency may cause decreased sperm count and motility as it is well established that chronic use of metformin is associated with 20-30% lower blood levels of vitamin B12. This hypothesis is further strengthened by the finding that vitamin B12 supplements improve fertility in animals with abnormal sperm production. In this way, Naglaa et al have questioned the justification for the use of metformin in a frame of a therapeutic strategy for diabetes due to its resulting impact on male fertility and also put forward probable reasons behind this (22). Moreover, vitamin B12 deficiency during pregnancy may induce irreversible damage in the germ cells of embryos and affect the maturation of spermatozoa. Chronic exposure of metformin induces DNA damage in mammalian cells (23) and also impairs the mitochondrial complex-1 activity which plays the vital role to maintain the normalcy of sperm motility (24).

However, another study by Morgante et al has shown that the use of metformin is associated with a statistically significant reduction in insulin resistance and sex hormone-binding globulin levels, a statistically significant increase in serum androgen levels, and a consequent improvement in semen characteristics (25). The results of present study demonstrate that the (mean±SE) before versus after 3 months of treatment with metformin of serum LH, FSH, E2, and testosterone shows no statistically significant differences while the level of serum prolactin reveal statistically significant decrease. Metformin may change the affinity and/or the number of dopamine receptors or of receptors for other compounds regulating production, secretion and metabolism of prolactin, may enhance gastrointestinal absorption and/or
metabolism of bromocriptine, as well as may
directly affect prolactin pharmacokinetics.
Interestingly, animal studies carried out
evidenced that metformin penetrates the
blood–brain barrier, and its content in the
pituitary is higher than in any other brain
structure (26). In the light of these results, it
seems that the pituitary is an important target
for metformin action and that the prolactin-
lowering effect of this agent results, at least in
part, from its action at the level of pituitary
lacotropes. Taking into account that this drug
was found to reduce plasma levels of other
pituitary hormones (27-28).
In conclusion, results of the current study
demonstrate that although metformin has the
capacity to decrease the BMI as well as level of
prolactin, it decreases the number and activity
of sperms. Further studies are recommended
to investigate whether there is any association
between infertility in human males and chronic
metformin use and in vitro effects of
metformin on human spermatozoa to observe
cytomorphometrical changes, biochemical
alterations

Acknowledgment
I would like to thank Dr. Ehab S. Hussein,
Professor Usama Al-Nasiri, and assistance
Professor Ahmed H. for supporting this project.

Conflict of interest
The author declares no conflict of interest.

Funding
Personal funding.

References
1. Bell PM, Hadden DR. Metformin. Endocrinol Metab
1993; 24:1299-1309.
protein kinase in mechanism of metformin action. J
4. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent
signaling pathways. Ann Rev Biochem. 2006; 75:137-
63.
5. Lobstein T, Rigby N, Leach R. EU platform on diet,
physical activity and health. International Obesity
reproductive health: British Fertility Society, policy
and practice guidelines. Hum Fertil. 2007; 10:195-
206.
of male obesity on infertility: a critical review of the
9. Shayeb AG, Bhattyachary S. Review: Male obesity and
9:7-12.
body mass index and infertility. Hum Reprod. 2007;
22:2488-93.
11. Ramlau-Hansen C, Thulstrup A, Nohr E, et al. Sub-
fecundity in overweight and obese couples. Hum
12. Sallmen M, Sandler D, Hoppin J, et al. Reduced
fertility among overweight and obese men.
Epidemiology. 2006; 17:520-3.
mass index values on sperm quantity and quality. J
Androl. 2007; 27:450-452.
mass index in relation to semen quality and
reproductive hormones among 1,558 Danish men.
16. World Health Organiaization (WHO): WHO Laboratory
Manual For the examination of human Semen and
sperm- cervical interaction, New York, Cambrdge,
USA; 2010.
17. SPSS Win. Statistical Program Under Windows,
of metformin with non-obese type 2 diabetes. J
of metformin in type 2 diabetes: results of a double-
blind, placebo-controlled dose-response trial. Am J
20. Defronzo RA. From the triumvirate to the ominous
octet: a new paradigm for the treatment of type 2
children and adolescents: The MOCA Trial. J Clin
of Metformin on immunity and male fertility in


Correspondence to Dr. Ahmed R. Abu-Raghif
E-mail: ar_armat1967@yahoo.com
Tel. + 964 77275598
Received 25th Jun. 2015: Accepted 30th Sep. 2015